Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

Patent ExpiryEftilagimod AlfaPositive

AI Analysis

Summary

Immutep secured a fourth U.S. patent for eftilagimod alfa in combination with a PD-1 pathway inhibitor, strengthening intellectual property protection for the combination therapy approach.

Outcome Details

Fourth U.S. patent secured for eftilagimod alfa in combination with a PD-1 pathway inhibitor

Importance:4/10

Sentiment:

0.60

patentintellectual propertyeftilagimod alfaPD-1 inhibitorimmunotherapy

Related Companies

$IMMP

Read the original article

Published by yahoo_finance on July 14, 2026 12:00 PM

Read Original